Checkpoint Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of immune checkpoint inhibitors for the treatment of cancer. Its drug candidates target the PD-1/PD-L1 pathway, a key immune checkpoint that cancer cells use to avoid detection by the immune system. With a strong pipeline and a commitment to improving patient outcomes, Checkpoint Therapeutics is poised to make significant contributions in the fight against cancer.
Notification